| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Bone Marrow Cells May Significantly Reduce Risk of Second Myocardial Infarction DALLAS -- December 10, 2009 -- After surviving a myocardial infarction (MI), cells from a patients’ own bone marrow reduced the risk of death or another MI when they were infused into the affected artery after successful stent placement, according to a study published in the journal Circulation: Heart Failure. Benefits found early in the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial could last for at least 2 years, researchers said. “More research is needed, but this gives us a hint of what might be possible with this new treatment -- prevention of another heart attack and of rehospitalisation for heart failure, both life-threatening complications,” said first author Birgit Assmus, MD, J.W. Goethe University, Frankfurt, Germany. Researchers conducted the study at 17 centres in Germany and Switzerland. They randomised 101 MI survivors to receive a solution including progenitor cells from their own bone marrow. The other 103 patients received a placebo solution. Researchers infused cells or placebo into the artery that triggered patients’ MIs 3 to 7 days after undergoing reperfusion therapy. “The goal of this study was to prevent heart failure by enhancing new vessel growth and perfusion of the surviving tissue,” said Dr. Assmus. At 2 years, no patients from the bone marrow cell group had suffered a MI while 7 patients from the placebo group had. Compared with placebo patients, cell-infused patients were less likely to die (3 vs 8 in placebo group), need new revascularizations (25 vs 38), or be rehospitalised for heart failure (1 vs5). “Large, randomised trials are urgently needed to assess the effects of progenitor-cell therapy in patients with heart attacks,” Dr. Assmus said.
SOURCE: American Heart Association
|